NewsFeed Voices Science Insight Innovation
November, 2025
November 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
Jamal Rana: The LDL Cholesterol Goal Post Has Moved
Jamal Rana/LinkedIn
Nov 10, 2025, 01:53

Jamal Rana: The LDL Cholesterol Goal Post Has Moved

Jamal Rana, Professor in the Department of Clinical Science at Kaiser Permanente Bernard J. Tyson School of Medicine, shared on LinkedIn:

”Goal post to treat LDL cholesterol has moved in patients with high risk for heart disease. Was thrilled to be part of The Wall Street Journal coverage of the biggest trials presented at AHA Scientific Sessions. We are now in era where multiple options exist to aggressively treat LDL cholesterol in high risk patients to prevent heart disease.

A PCSK9 inhibitor, evolocumab or Repatha, used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo when used in patients without a prior history of myocardial infarction or stroke, the VESALIUS-CV study shows over a median follow-up of 4.6 years.

A single injection of a gene-edited protein was deemed productive and safe in patients with dyslipidemia that was unresponsive to lipid-lowering therapy, according to a phase I trial. IV CTX310 is an in vivo CRISPR-Cas9 gene-editing drug product targeting ANGPTL3.

CORALreef Lipids trial demonstrated that treatment with enlicitide decanoate, once-daily oral PCSK9-inhibitor, resulted in a statistically significant and clinically meaningful reduction in LDL cholestrol.”

Jamal Rana

Check here for more information.

Stay updated on all scientific advances with Hemostasis Today.

Betsy McKay Cholesterol Evolocumab Health Heart Disease Hematology Hemostasis Today Jamal Rana LDL Lipid Lowering Therapy Medicine PCSK9 inhibitor thrombosis
NewsFeed